Treatment for long-term effects of COVID-19
Therapy for long-COVID in a preclinical model
This study is looking at a possible treatment using a compound called homotaurine to help people who are dealing with long-lasting brain fog, anxiety, and depression after having COVID-19, especially from the Omicron variant.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11136994 on NIH RePORTER |
What this research studies
This research investigates potential therapies for patients experiencing long-term neurological symptoms after COVID-19 infection, particularly those caused by the Omicron variant. The approach focuses on using a compound called homotaurine, which activates specific receptors in the brain to reduce inflammation and improve cognitive function. By studying this in a preclinical model, researchers aim to understand how this treatment can alleviate symptoms like 'brain fog', anxiety, and depression that affect many recovering COVID-19 patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recovered from COVID-19 but are experiencing persistent neurological symptoms.
Not a fit: Patients who have not been infected with COVID-19 or those without neurological symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for long-COVID symptoms, improving the quality of life for many patients.
How similar studies have performed: There is emerging evidence that similar approaches targeting neuroinflammation have shown promise in other conditions, suggesting potential for success in this area as well.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Kaufman, Daniel — University of California Los Angeles
- Study coordinator: Kaufman, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.